HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bunn, P. A. Articles by Kelly, K. Search for Related Content PubMed PubMed Citation Articles by Bunn, P. A., Jr Articles by Kelly, K.

Adjuvant and Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer^*

A Time for Reassessment?

^* From the Lung Cancer Program and Departments of Medicine (Drs. Bunn and Kelly) and Surgery (Dr. Mault), University of Colorado Cancer Center, Denver, CO.

Correspondence to: Paul A. Bunn, Jr, MD, University of Colorado Cancer Center, Box B-188, 4200 East 9th Ave, Denver, CO 80262; e-mail: paul.bunn{at}uchsc.edu

Surgical resection has limited success in curing non-small cell lung cancer (NSCLC), particularly among patients with locally advanced disease (stage IIIA). Combined modality regimens, utilizing surgery, radiotherapy, and chemotherapy, have improved response rates, although they have not been shown to significantly impact survival among patients with completely resected stage I and II NSCLC. Future improvements in NSCLC therapy, currently under investigation, are likely to come from newer agents shown to be active in this disease and from alternative schedules, such as neoadjuvant or concurrent combined modality treatments. Neoadjuvant cisplatin-based chemotherapy has already been shown to increase cure rates in stage IIIA NSCLC, from 10 to 15% to 25 to 30%. Newer active agents, such as paclitaxel, vinorelbine, and gemcitabine, may be able to advance the cure rate even further. Radiotherapy, which has been shown to decrease the rate of local recurrence, may play a role as well.

Key Words: adjuvant therapy • cisplatin • lymph nodes • neoadjuvant therapy • non-small cell lung cancer • radiotherapy • recurrence

This article has been cited by other articles:

				A. Marra, L. Hillejan, G. Zaboura, T. Fujimoto, D. Greschuchna, and G. Stamatis Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 543 - 553. [Abstract] [Full Text] [PDF]